Skip to main content

Advertisement

SpringerLink
Log in

Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

  • Letter to the Editor (by invitation)
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bahrami B, Hong T, Zhu M, Schlub TE, Chang A (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-017-3624-y

    Google Scholar 

  2. Early Treatment Diabetic Retinopathy Study research group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806

    Article  Google Scholar 

  3. Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120:2013–2022

    Article  PubMed  Google Scholar 

  4. Wells JA, Glassman AR, Ayala AR et al (2016) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 123:1351–1359

    Article  PubMed  PubMed Central  Google Scholar 

  5. Korobelnik JF, Do DV, Schmidt-Erfurth U et al (2014) Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:2247–2254

    Article  PubMed  Google Scholar 

  6. Ahmadieh H, Ramezani A, Shoeibi N et al (2008) Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 246:483–489

  7. Bahrami B, Zhu M, Hong T, Chang A (2016) Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 59:1594–1608

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sydney Institute of Vision Science, 13/187 Macquarie Street, Sydney, NSW, 2000, Australia

    Bobak Bahrami, Thomas Hong & Andrew Chang

  2. Save Sight Institute, University of Sydney, Sydney, NSW, Australia

    Bobak Bahrami & Andrew Chang

Authors
  1. Bobak Bahrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Chang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bahrami, B., Hong, T. & Chang, A. Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255, 1453–1454 (2017). https://doi.org/10.1007/s00417-017-3670-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-017-3670-5

Keywords

Search

Navigation